Product Images Eylea

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 22 images provide visual information about the product associated with Eylea NDC 61755-005 by Regeneron Pharmaceuticals, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 6 - eylea 01

Figure 6 - eylea 01

Figure 1 - eylea 01a

Figure 1 - eylea 01a

This is a description of various parts of a syringe including a syringe cap, Luer lock, 0.05 ml dosing line, plunger, finger grip, and plunger rod.*

Figure 2 - eylea 01b

Figure 2 - eylea 01b

Figure 3 - eylea 01c

Figure 3 - eylea 01c

Figure 4 - eylea 01d

Figure 4 - eylea 01d

Figure 5a - eylea 01e

Figure 5a - eylea 01e

Figure 5b - eylea 01f

Figure 5b - eylea 01f

Figure 7 - eylea 02

Figure 7 - eylea 02

Figure 8 - eylea 03

Figure 8 - eylea 03

Figure 9a - eylea 04

Figure 9a - eylea 04

Figure 9b - eylea 04a

Figure 9b - eylea 04a

Figure 10 - eylea 05

Figure 10 - eylea 05

Figure 11 - eylea 06

Figure 11 - eylea 06

Figure 12a - eylea 07

Figure 12a - eylea 07

Figure 12b - eylea 07a

Figure 12b - eylea 07a

Figure 13 - eylea 08

Figure 13 - eylea 08

Mean change in visual acuity is being measured over a period of up to 96 weeks for multiple treatments including EYLEA at 2mg quantity every 8 or 4 weeks, as well as Ranibizumab at 0.5mg every 4 weeks. Visual acuity is measured in letters and recorded at various timepoints throughout the study.*

Figure 14 - eylea 09

Figure 14 - eylea 09

Figure 15 - eylea 10

Figure 15 - eylea 10

This appears to be a chart or graph showing the mean change in visual acuity in letters after 4, 8, 12, 16, 20, and 24 weeks for a group of patients who received EYLEA 2 mg Q4 weeks and a control group. The numbers on the left and right probably indicate visual acuity scores, and the plus signs and numerical values likely indicate the change in scores from the baseline.*

Figure 16 - eylea 11

Figure 16 - eylea 11

The text describes a comparison study of the mean change in visual acuity over weeks, between a group receiving EYLEA 2mg every 8 weeks and another group receiving it every 4 weeks. There are also two columns of letters next to the visual acuity data, but there is no information about them.*

Figure 17 - eylea 11a

Figure 17 - eylea 11a

Not-Available*

PRINCIPAL DISPLAY PANEL - 2 mg/0.05 mL Vial Carton - eylea 12

PRINCIPAL DISPLAY PANEL - 2 mg/0.05 mL Vial Carton - eylea 12

EYLEA is a medication used for intravitreal injection. It is supplied in a single-use vial and comes with a plastic syringe, two needles and a package insert. The medication contains the active ingredient aflibercept and has a strength of 2mg/0.05.*

PRINCIPAL DISPLAY PANEL - 2 mg/0.05 mL Syringe Carton - eylea 13

PRINCIPAL DISPLAY PANEL - 2 mg/0.05 mL Syringe Carton - eylea 13

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.